{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:53:05Z","timestamp":1771948385443,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000},"content-version":"am","delay-in-days":264,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Biocodex (Beauvais, France)"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 082635"],"award-info":[{"award-number":["R01 082635"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.eplepsyres.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T12:17:33Z","timestamp":1555330653000},"page":"8-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The therapeutic effect of stiripentol in Gabrg2 mice associated with epileptic encephalopathy"],"prefix":"10.1016","volume":"154","author":[{"given":"Timothy A.","family":"Warner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas K.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-Qiong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0005","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/epi.12401","article-title":"Stiripentol exhibits higher anticonvulsant properties in the immature than in the mature rat brain","volume":"54","author":"Auvin","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0010","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1528-1167.2012.03497.x","article-title":"Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome","volume":"53","author":"Cao","year":"2012","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"10.1016\/j.eplepsyres.2019.04.006_bib0015","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2011.03007.x","article-title":"The pharmacologic treatment of Dravet syndrome","volume":"52","author":"Chiron","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0020","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0025","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2010.12.037","article-title":"Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines","volume":"654","author":"Fisher","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141221","article-title":"Repeated 6-Hz corneal stimulation progressively increases FosB\/DeltaFosB levels in the lateral amygdala and induces seizure generalization to the hippocampus","volume":"10","author":"Giordano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0035","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1086\/338710","article-title":"Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus","volume":"70","author":"Harkin","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1528-1157.1990.tb05494.x","article-title":"Epidemiology of severe myoclonic epilepsy of infancy","volume":"31","author":"Hurst","year":"1990","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0045","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","article-title":"Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan","volume":"113","author":"Inoue","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0050","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1523\/JNEUROSCI.4772-08.2009","article-title":"The GABRG2 mutation, Q351X, associated with generalized epilepsy with febrile seizures plus, has both loss of function and dominant-negative suppression","volume":"29","author":"Kang","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0055","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ana.23947","article-title":"Trafficking-deficient mutant GABRG2 subunit amount may modify epilepsy phenotype","volume":"74","author":"Kang","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0060","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nn.4024","article-title":"The human epilepsy mutation GABRG2(Q390X) causes chronic subunit accumulation and neurodegeneration","volume":"18","author":"Kang","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0065","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/338582a0","article-title":"Importance of a novel GABAA receptor subunit for benzodiazepine pharmacology","volume":"338","author":"Pritchett","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.eplepsyres.2019.04.006_bib0070","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","article-title":"Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels","volume":"47","author":"Quilichini","year":"2006","journal-title":"Epilepsia"},{"issue":"Aug. (15)","key":"10.1016\/j.eplepsyres.2019.04.006_bib0075","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1093\/hmg\/ddw168","article-title":"DIfferential molecular and behavioral alterations in mouse models of GABRG2 haploinsufficiency versus dominant negative mutations associated with human epilepsy","volume":"25","author":"Warner","year":"2016","journal-title":"Hum. Mol. Genet."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119300543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119300543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:41:03Z","timestamp":1760276463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121119300543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":15,"alternative-id":["S0920121119300543"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.04.006","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic effect of stiripentol in Gabrg2+\/Q390X mice associated with epileptic encephalopathy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}